CNS lymphoma treatment market seen reaching $1.76 billion by 2030

The central nervous system lymphoma treatment market is projected to rise from $1.27 billion in 2025 to $1.76 billion by 2030, driven by broader use of immunotherapy, targeted treatments and personalized care. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The central nervous system lymphoma treatment market is moving toward broader use of newer cancer therapies that could improve outcomes and reduce toxicity for patients with brain, spinal cord or cerebrospinal fluid lymphoma. - The market expansion signals more investment in oncology drugs, diagnostics and treatment infrastructure for a rare and difficult-to-treat cancer.

What happened: - The central nervous system lymphoma treatment market is projected to grow from $1.27 billion in 2025 to $1.36 billion in 2026. - The market is forecast to reach $1.76 billion by 2030. - The report projects a 6.9% compound annual growth rate in 2026 and a 6.6% CAGR over the 2026-2030 period. - The Business Research Company released the market outlook on Nov. 11, 2026. - The report covers treatment approaches for lymphoma affecting the brain, spinal cord or cerebrospinal fluid.

The details: - Common treatment regimens include high-dose methotrexate-based chemotherapy, immunotherapy, radiation therapy and autologous stem cell transplantation. - Treatment plans are tailored to a patient’s age, overall health and disease severity. - The report says market growth has been supported by improved survival rates from high-dose chemotherapy, expanded oncology infrastructure, stronger clinical research on hematologic cancers, greater awareness of primary CNS lymphoma and wider use of advanced imaging. - The market outlook points to rising adoption of CAR-T cell therapies and targeted immunotherapies. - Other growth factors include higher investment in oncology drug development, broader use of personalized oncology care models, demand for less toxic regimens and a stronger focus on long-term remission. - Major forecast-period trends include more immunotherapy-based treatment, wider use of targeted therapies for CNS lymphoma, more combination therapy approaches, personalized treatment strategies and improved diagnostic monitoring. - The report says the pharmaceutical industry is a key growth driver because it supports drug research, development, manufacturing and distribution. - European pharmaceutical production reached $417.3 billion (€390 billion) in 2023, up from $388.141 billion (€363.3 billion) in 2022, according to the European Federation of Pharmaceutical Industries and Associations. - Personalized medicine is also accelerating market growth by tailoring treatment to genetic, environmental and lifestyle factors. - The Personalized Medicine Coalition said the FDA approved seven new personalized cancer treatments in 2023, bringing the total to 26 personalized therapies, up from 12 approvals in 2022. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics. - The report is available as a free sample and as a full market report through The Business Research Company’s website, including the free sample request page and the full market report.

Between the lines: - The forecast points to a market that is being shaped less by legacy chemotherapy alone and more by targeted, precision-based treatment strategies. - North America held the largest market share in 2025, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also includes South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional analysis.

What's next: - Growth is likely to depend on how quickly CAR-T therapies, targeted immunotherapies and personalized medicine gain wider clinical adoption. - The fastest gains may come from regions expanding access to oncology care and advanced diagnostics. - The report’s forecast suggests the market will keep building through 2030 as treatment options broaden and more patients are diagnosed earlier.

The bottom line: - CNS lymphoma treatment is shifting toward more precise and less toxic care, and that shift is expected to keep pushing the market higher through 2030.